18F-PET-CT in extracranial paediatric oncology: When and for whom is it useful?

Pediatric Radiology

Volumn 38, Issue SUPPL. 3, 2008, Pages

  Kaste, Sue C ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

CANCER RADIOTHERAPY; CANCER STAGING; CHILDHOOD CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; HISTIOCYTOSIS X; HUMAN; LUNG NODULE; LYMPHOMA; NEPHROBLASTOMA; NEUROBLASTOMA; NEUROFIBROMATOSIS; PRIORITY JOURNAL; REVIEW; SARCOMA; SOLID TUMOR; CHILD; NEOPLASM; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING;

CHILD; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 43549084137     PISSN: 03010449     EISSN: 14321998     Source Type: Journal    
DOI: 10.1007/s00247-008-0839-4     Document Type: Review

References (45)

1. Kaste SC (2004) Issues specific to implementing PET-CT for pediatric oncology: what we have learned along the way. Pediatr Radiol 34:205-213
2. Agress H Jr, Cooper BZ (2004) Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison. Radiology 230:417-422
3. Shulkin BL, Mitchell DS, Ungar DR et al (1995) Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-d-glucose PET studies. Radiology 194:495-500
4. Kaste SC, Dome JS (2006) PET/PET-CT imaging of Wilms tumor. In: Charron M (ed) Practical pediatric PET imaging. Springer, New York
5. Brenner W, Bohuslavizki KH, Eary JF (2003) PET imaging of osteosarcoma. J Nucl Med 44:930-942
6. Franzius C, Daldrup-Link HE, Wagner-Bohn A et al (2002) FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. Ann Oncol 13:157-160
7. Gyorke T, Zajic T, Lange A et al (2006) Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumours. Nucl Med Commun 27:17-24
8. Lucas JD, O'Doherty MJ, Wong JC et al (1998) Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br 80:441-447
9. Shad A, Magrath I (1997) Malignant non-Hodgkin's lymphomas in children. In: Pizzo PA, Poplack DG (eds) Principles and practice of pediatric oncology. Lippincott Raven, Philadelphia, pp 545-587
10. Rini JN, Leonidas JC, Tomas MB et al (2003) 18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma. J Nucl Med 44:1072-1074
11. Depas G, De Barsy C, Jerusalem G et al (2005) 18F-FDG PET in children with lymphomas. Eur J Nucl Med Mol Imaging 32:31-38
12. Montravers F, McNamara D, Landman-Parker J et al (2002) [(18)F]FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med Mol Imaging 29:1155-1165
13. Bar-Sever Z, Keidar Z, Ben Barak A et al (2007) The incremental value of 18F-FDG PET/CT in paediatric malignancies. Eur J Nucl Med Mol Imaging 34:630-637
14. Krasin MJ, Hudson MM, Kaste SC (2004) Positron emission tomography in pediatric radiation oncology: integration in the treatment-planning process. Pediatr Radiol 34:214-221
15. Mutic S, Grigsby PW, Low DA et al (2002) PET-guided three-dimensional treatment planning of intracavitary gynecologic implants. Int J Radiat Oncol Biol Phys 52:1104-1110
16. Mutic S, Malyapa RS, Grigsby PW et al (2003) PET-guided IMRT for cervical carcinoma with positive para-aortic lymph nodes-a dose-escalation treatment planning study. Int J Radiat Oncol Biol Phys 55:28-35
17. Caldwell CB, Mah K, Ung YC et al (2001) Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: the impact of 18FDG-hybrid PET fusion. Int J Radiat Oncol Biol Phys 51:923-931
18. Mah K, Caldwell CB, Ung YC et al (2002) The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys 52:339-350
19. Erdi YE, Rosenzweig K, Erdi AK et al (2002) Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 62:51-60
20. Nanni C, Rubello D, Castellucci P et al (2006) 18F-FDG PET/CT fusion imaging in paediatric solid extracranial tumours. Biomed Pharmacother 60:593-606
21. Hawkins DS, Rajendran JG, Conrad EU III et al (2002) Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-d-glucose positron emission tomography. Cancer 94:3277-3284
22. McCarville MB, Christie R, Daw NC et al (2005) PET/CT in the evaluation of childhood sarcomas. AJR 184:1293-1304
23. Franzius C, Daldrup-Link HE, Sciuk J et al (2001) FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 12:479-486
24. Aoki J, Watanabe H, Shinozaki T et al (2001) FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology 219:774-777
25. Franzius C, Bielack S, Flege S et al (2002) Prognostic significance of (18)F-FDG and (99m)Tc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med 43:1012-1017
26. Schulte M, Brecht-Krauss D, Werner M et al (1999) Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 40:1637-1643
27. Shulkin BL, Hutchinson RJ, Castle VP et al (1996) Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-d-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 199:743-750
28. Kushner BH, Yeung HW, Larson SM et al (2001) Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 19:3397-3405
29. Miyake M, Tateishi U, Maeda T et al (2006) A case of ganglioneuroma presenting abnormal FDG uptake. Ann Nucl Med 20:357-360
30. Azouz EM, Saigal G, Rodriguez MM et al (2005) Langerhans' cell histiocytosis: pathology, imaging and treatment of skeletal involvement. Pediatr Radiol 35:103-115
31. Binkovitz LA, Olshefski RS, Adler BH (2003) Coincidence FDG-PET in the evaluation of Langerhans' cell histiocytosis: preliminary findings. Pediatr Radiol 33:598-602
32. Jubran RF, Marachelian A, Dorey F et al (2005) Predictors of outcome in children with Langerhans cell histiocytosis. Pediatr Blood Cancer 45:37-42
33. Kaste SC, Rodriguez-Galindo C, McCarville ME et al (2007) PET-CT in pediatric Langerhans cell histiocytosis. Pediatr Radiol 37:615-622
34. Bredella MA, Torriani M, Hornicek F et al (2007) Value of PET in the assessment of patients with neurofibromatosis type 1. AJR 189:928-935
35. Chander S, Westphal SM, Zak IT et al (2004) Retroperitoneal malignant peripheral nerve sheath tumor: evaluation with serial FDG-PET. Clin Nucl Med 29:415-418
36. Cardona S, Schwarzbach M, Hinz U et al (2003) Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours. Eur J Surg Oncol 29:536-541
37. Son JM, Ahn MI, Cho KD et al (2007) Varying degrees of FDG uptake in multiple benign neurofibromas on PET/CT. Br J Radiol 80:e222-e226
38. Barrington SF, O'Doherty MJ (2003) Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging 30 Suppl 1:S117-S127
39. Shreve PD, Bui CD (2002) Normal variants in FDG PET Imaging. In: Wahl RL, Buchanan JW (eds) Principles and practice of positron emission tomography. Lippincott, Williams and Wilkins, Philadelphia, pp 111-136
40. Lerman H, Metser U, Grisaru D et al (2004) Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. J Nucl Med 45:266-271
41. Yeung HW, Grewal RK, Gonen M et al (2003) Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. J Nucl Med 44:1789-1796
42. Hudson MM, Krasin MJ, Kaste SC (2004) PET imaging in pediatric Hodgkin's lymphoma. Pediatr Radiol 34:190-198
43. Hollingshead LM, Goa KL (1991) Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions. Drugs 42:300-330
44. Hollinger EF, Alibazoglu H, Ali A et al (1998) Hematopoietic cytokine-mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging. Clin Nucl Med 23:93-98
45. Sugawara Y, Fisher SJ, Zasadny KR et al (1998) Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol 16:173-180